MANF Therapeutics Announces Positive MANF Pre-Clinical Data inAlpha-Synuclein Model of Parkinson's DiseasePublished in Peer-Reviewed Journal Experimental Neurobiology
July 09, 2018 08:00 ET
|
Amarantus Bioscience Holdings, Inc.
NEW YORK, July 09, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- MANF Therapeutics, Inc., a wholly-owned subsidiary of Amarantus Bioscience Holdings, Inc. (OTCPK:AMBS) in pre-clinical development...
MANF Therapeutics Announces Independent Publication of Positive Data for MANF in Traumatic Brain Injury Animal Model
June 11, 2018 07:00 ET
|
Amarantus Bioscience Holdings, Inc.
NEW YORK, June 11, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE--MANF Therapeutics, Inc., a wholly-owned subsidiary of Amarantus Bioscience Holdings, Inc. (OTCPK:AMBS) in pre-clinical development...
Amarantus Provides Update on Elto Pharma Capital Formation Plan
June 07, 2018 09:08 ET
|
Amarantus Bioscience Holdings, Inc.
NEW YORK, June 07, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire – Amarantus Bioscience Holdings, Inc. (OTC Pink:AMBS) (the "Company," or AMBS), a US-based, JLABS-alumnus biotechnology holding...
MANF Therapeutics Announces Publication of Positive Data for MANF in Stroke Animal Model in AAAS Journal Science Advances
June 05, 2018 08:11 ET
|
Amarantus Bioscience Holdings, Inc.
NEW YORK, June 05, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire -- MANF Therapeutics, Inc., a wholly-owned subsidiary of Amarantus Bioscience Holdings, Inc. (OTCPK:AMBS) in pre-clinical development...
Amarantus Exercises Exclusive Option with Leipzig University for Alzheimer's Blood Diagnostic "LymPro Test 2.0"
May 30, 2018 08:00 ET
|
Amarantus Bioscience Holdings, Inc.
Scope of exercised Exclusive Option Agreement expanded to include negotiations for IP rights to additional key markers collected in German clinical study, including CSF-tau NEW YORK, May 30, 2018 ...
Amarantus to Present at LD Micro and The Reg A Conference
May 24, 2018 11:00 ET
|
Amarantus Bioscience Holdings, Inc.
NEW YORK, May 24, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire -- Amarantus Bioscience Holdings, Inc. (OTCPink:AMBS) (the "Company," or AMBS), a US-based JLABS-alumnus biotechnology holding company,...
Amarantus Retains Weild & Co. to Advise on JOBS Act Funding
May 22, 2018 06:00 ET
|
Amarantus Bioscience Holdings, Inc.
Mr. Heng Fai Chan converts secured debt into common equity NEW YORK, May 22, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Amarantus Bioscience Holdings, Inc. (OTC Pink:AMBS) (the "Company," or...
MANF Therapeutics Announces Publication in Society for Neuroscience eNeuro Journal of Human Ocular Distribution and Animal Photoreceptor Protection Data for MANF
May 21, 2018 08:40 ET
|
Amarantus Bioscience Holdings, Inc.
NEW YORK, May 21, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire -- MANF Therapeutics, Inc., a wholly-owned subsidiary of Amarantus Bioscience Holdings, Inc. (OTCPK:AMBS) in pre-clinical development...
Amarantus Provides Business Overview
May 11, 2018 10:25 ET
|
Amarantus Bioscience Holdings, Inc.
NEW YORK, May 11, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire -- Amarantus Bioscience Holdings, Inc. (OTC Pink:AMBS) (the "Company," or AMBS), a US-based JLABS-alumnus biotechnology holding company,...
Amarantus Enters into Exclusive Option Agreement with Leipzig University to License IP Covering Alzheimer's Blood Diagnostic LymPro Test 2.0 Blood Test vs. Amyloid PET
May 04, 2018 08:45 ET
|
Amarantus Bioscience Holdings, Inc.
NEW YORK, May 04, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire -- Amarantus Bioscience Holdings, Inc. (OTC Pink:AMBS) (the "Company" or AMBS), a US-based JLABS-alumnus biotechnology holding company,...